In sterile pharmaceutical manufacturing, alarms aren't just disruptive buzzers, they’re critical sentinels that ensure patient safety. With the European Medicines Agency's (EMA) revised GMP Annex 1 now fully enforced since August 2023, the pressure is on for continuous, real-time alarm monitoring across cleanrooms and processes. Many manufacturers are still grappling with fragmented manual systems, but a new spotlight in World Pharmaceutical Frontiers magazine highlights how Aizon Unify is turning this regulatory mandate into a strategic opportunity.
Our latest feature, Ringing the Alarm: Unified Data for GMP Annex 1 Compliance, provides insight into the collaboration between Aizon and OYTEC. With compliance as a starting point, this partnership empowers pharma leaders to break data silos, contextualize alarms, and drive proactive improvements, while putting a host of new digital capabilities at their fingertips.
The Regulatory Wake-Up Call
Section 5.2 of GMP Annex 1 is crystal clear:
“Equipment monitoring requirements should be defined in “user requirements specifications” (…) Process and equipment alarm events should be acknowledged and evaluated for trends. The frequency at which alarms are assessed should be based on their criticality (with critical alarms reviewed immediately).”
Manual logs and delayed reviews are not enough anymore. Real-time acknowledgment, contextual evaluation, and trend analysis are now demanded.
From Silos to Real-Time Intelligence
Enter Aizon Unify: our pharma-native, GxP-compliant lakehouse designed from the ground up for regulated environments. In partnership with OYTEC, we delivered a solution that transformed alarm management for a leading European sterile manufacturer in under three months.
But the benefits don’t end with compliance. By breaking data silos and unifying and contextualizing data, Aizon Unify provides real-time visibility, enabling instant dashboard views and historical trend analysis, empowering teams to investigate root causes. As Aizon VP of Technical Sales Cristian Marfà explains in the article, “You get compliance plus a slew of optimizations. The savings and improvements really speak for themselves.”
As for the future, Team Lead Data Consultant Fran Puerto says it best: "With data now clean and accessible, AI-driven models are a logical next step."
Read the full article here:
Ringing the alarm: Unified data for GMP Annex 1 compliance
The EMA’s revised GMP Annex 1, fully enforced since August 2023, has intensified demand for alarm monitoring from sterile manufacturers, many of which, lacking a digital solution, are still wrestling with manual processes to achieve this. A successful collaboration between Aizon and OYTEC for a leading European pharmaceutical company shows how this regulatory requirement can be turned, in a matter of weeks, into a strategic advantage. To learn more, we sit down with Cristian Marfà, VP of technical sales at Aizon; Fran Puerto, team lead data consultant at Aizon; and Jordi Pujadó-Coll, technical director at OYTEC.
The 2023 revision of EU GMP Annex 1 has put a spotlight on alarm monitoring. Can you start by outlining how your recent partnership with OYTEC helped a client navigate this?
Cristian Marfà: GMP Annex 1 requires alarm monitoring as part of its updated Contamination Control Strategy. Our client faced the challenge of achieving alarm monitoring across almost 50 different machines. OYTEC’s expertise in on-site machine connectivity was key here. They integrated sensors and devices seamlessly, capturing real-time data from all the equipment.
Jordi Pujadó-Coll: At OYTEC, we specialise in pharma digitalisation, so that’s really our bread and butter. For this project, we connected all the machines into Aizon Unify to ensure data flowed securely and in real time.
Fran Puerto: Aizon Unify is our GMP-compliant platform. Unify doesn’t just store data; it contextualises it, linking alarms to batches, processes and equipment. We began by auditing the site’s alarms – counting occurrences, grouping them by type, and categorising them into ‘GMP-critical’ and ‘non-GMP’ ones. This helped the client turn noise into actionable intelligence.
Many manufacturers view alarm monitoring as a box-ticking exercise for Annex 1 compliance. How has this project shown its broader value?
CM: It’s quite common that a company starts with compliance and then uncovers a goldmine for improvement.
JPC: Seeing the data unified on site is eye-opening. Previously, alarms were siloed. Now, they can spot patterns. It’s empowering the team to move from reactive firefighting to proactive maintenance, all while staying compliant.
FP: And let’s not forget the analytics layer. Unify’s real-time capabilities let you run queries on the fly. Beyond alarms, clients can leverage unified data to unlock many additional efficiencies. compliance was the entry point, but now they’re eyeing full digital transformation.
How does Aizon Unify go beyond basic monitoring to enable process improvements?
CM: Unify is designed as a ‘GMP by design’ platform that aggregates data from any source. In this case, it broke silos across the site, providing a single view for all manufacturing data. Alarms aren’t isolated events anymore; now they’re tied to context, like batch ID or operator logs. And this foundation opens doors to advanced solutions, such as AI-powered predictive analytics with Aizon Predict.
FP: With data now clean and accessible, AI-driven models are a logical next step. We’ve seen clients use predictive analytics to boost yields through optimised parameters.
JPC: The partnership amplified this. OYTEC handled the on-site connectivity, ensuring data quality, while Aizon handled the intelligence. The client is now requesting additional dashboards and discovering all the ways they can leverage their newly contextualised data. Annex 1 compliance was the entry point, but now they’re eyeing full digital transformation.
What advice would you give other sterile manufacturers hesitating on alarm monitoring?
CM: I would say, don’t view it as a cost but as an investment. With partners like OYTEC and Aizon, you get compliance plus a slew of optimisation solutions, as well as AI-readiness. The savings and improvements really speak for themselves.
JPC: I agree. As is becoming increasingly apparent, contextualised data is the new currency in pharma. It goes beyond compliance into competitive advantage. And fewer alarms mean more focus on innovation.
